Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 16/20 | 0.53 |
| ▸ | NOS1 | P29475 | 16/20 | 0.53 |
| ▸ | NOS2 | P35228 | 10/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499119 | 0.92 | NOS3 (0.62) | NOS3NOS1NOS2ALDH1A1NPC1 | |
| SCHEMBL15787121 | 0.90 | NOS3 (0.50) | NOS3NOS1NOS2KCNH2ALDH1A1 | |
| SCHEMBL13521877 | 0.89 | NOS3 (0.52) | NOS3NOS1NOS2ALDH1A1NPC1 | |
| SCHEMBL499436 | 0.88 | NOS3 (0.48) | NOS3NOS1NOS2ALDH1A1NPC1 | |
| SCHEMBL499625 | 0.85 | NOS1 (0.65) | NOS3NOS1NOS2ALDH1A1NPC1 | |
| SCHEMBL10268515 | 0.85 | NOS3 (0.56) | NOS3NOS1NOS2ALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL499392 | 0.84 | NOS1 (0.64) | NOS3NOS1NOS2ALDH1A1NPC1 | |
| SCHEMBL499325 | 0.84 | NOS3 (0.62) | NOS3NOS1NOS2ALDH1A1NPC1 | |
| SCHEMBL500048 | 0.84 | NOS3 (0.44) | NOS3NOS1NOS2ALDH1A1NPC1 | |
| SCHEMBL2677052 | 0.83 | NOS3 (0.62) | NOS3NOS1NOS2KCNH2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | NOS3 3/4885NOS1 2/4885NOS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.